## **Amendments to the Claims**

The listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims:**

1. - 27. (cancelled)

28. (currently amended) A method of screening a candidate compound for the ability to inhibit dimer assembly and secretion of a dimeric form of interleukin, comprising the steps of:

incubating a cell culture comprising a cell line transfected with an expression vector comprising DNA encoding a subunit of a dimeric form of interleukin under transcriptional control of an ecdysone-inducible promoter with the candidate compound;

inducing transcription of the dimeric interleukin in the cells of the culture using ecdysone or an ecdysone analog; and

assaying the cell culture for the presence of secreted interleukin.

- 29. (previously presented) The method as claimed in Claim 28, in which the interleukin expressed by the cell line has a 6 x histidine amino acid sequence tagged on either or both of the subunits thereof, wherein the assaying step involves Ni-NTA affinity chromatography.
- 30. (previously presented) The method as claimed in Claim 28 in which the assaying step involves probing the cell culture with an antibody specific to a dimeric form of interleukin, or a subunit thereof.
- 31. (cancelled)

Appl. No. 10/537,647 AMENDMENT Reply to June 24, 2010 Office Action

- 32. (cancelled) 33. (cancelled) 34. (cancelled) 35. (cancelled) 36. (cancelled) 37. (cancelled) 38. (cancelled) 39. (cancelled) 40. (cancelled)
- 42. (previously presented) The method according to Claim 28 wherein the subunit of dimeric form of interleukin is selected from the group consisting of p35 (alpha) subunit of interleukin 12 (IL-12); p40 (beta) subunit of IL-12; p19 chain of IL-23; p40 subunit of IL-23; ebi3 subunit of IL-27; and p28 subunit of IL-27.
- 43. (previously presented) The method according to Claim 28 wherein the cell line is capable of producing heterodimeric IL-12, the cell line being transfected with an expression vector in which the DNA encodes a p40 subunit of IL-12 and an expression vector in which the DNA encodes a p35 subunit of IL-12.

41.

(cancelled)

Appl. No. 10/537,647 AMENDMENT Reply to June 24, 2010 Office Action

- 44. (previously presented) The method according to Claim 28 wherein the cell line is capable of producing heterodimeric IL-23, the cell line being transfected with an expression vector in which the DNA encodes a p40 subunit of IL-12 and an expression vector in which the DNA encodes a p19 subunit of IL-23.
- 45. (previously presented) The method according to Claim 28 wherein the cell line includes plasmid pVgRxR.
- 46. (previously presented) The method according to claim 28 in which the cell line comprises cells which are human embryonic kidney cells.
- 47. (previously presented) The method according to claim 28 in which the cell line comprises human embryonic kidney cells which include plasmid pVgRxR.
- 48. (previously presented) The method according claim 28 in which the cell line comprises cells which are natural  $\beta$  subunit-producing cells.
- 49. (previously presented) The method according to claim 28 in which the cell line is the cell line having ECACC accession number 03112701.